David Ricks, chief executive officer of Eli Lilly & Co., speaks during the China Development Forum in Beijing in March this year. Photographer: Qilai Shen/Bloomberg © 2026 Bloomberg Finance LP In the latest China pharmaceutical industry collaboration pact with a global drug leader, Abbisko said today it will work with U.S.-based Eli Lilly and Company…
Healthcare is one of the most lucrative industries where investors can find world-class businesses to buy and hold. Industry leaders can be unstoppable long-term wealth creators, though there’s no such thing as a perfect stock. Novo Nordisk (NYSE: NVO) and Zoetis (NYSE: ZTS) have taken their share of lumps recently. Still, each company pays its…
Novo Nordisk A/S (NYSE:NVO) is one of the best healthcare stocks under $50 to invest in. On February 5, BofA adjusted the price target on Novo Nordisk A/S (NYSE:NVO) to DKK 350 from DKK 400, reiterating a Neutral rating and lowering its EPS forecasts 7%-10% on the company’s weak 2026 guidance. Berenberg Lowers Novo Nordisk…
Weight-loss injections have fallen under the spotlight in Hong Kong after the Post discovered over-the-counter sellers operating locally, and a recent study found that nearly one in two residents was overweight or obese. The Post’s investigation found the prescription-only medicines were available for purchase on some online platforms and at a pharmacy without the need…
Online retailers and a Hong Kong pharmacy are offering slimming injections without prescriptions despite local authorities requiring a doctor’s approval before purchase, a Post investigation has found, with an expert warning it could lead to misuse. Weight-loss injections, which have been approved by Hong Kong authorities for use, have become increasingly popular around the world…
Novo Nordisk is cutting the out-of-pocket prices of its popular weight-loss drug Wegovy and diabetes drug Ozempic for some consumers. Current customers who pay for the drugs out of pocket — without the help of health insurance — will now be charged $349 per month, down from $499, the Danish drugmaker said Monday. Novo Nordisk…
President Donald Trump has announced a landmark deal aiming to expand Medicare coverage to include certain weight-loss medications, a move that could dramatically change access to these treatments for millions of older Americans. On November 6, Trump revealed that his administration had struck agreements with Eli Lilly and Novo Nordisk, the makers of popular weight-loss…
(Reuters) -Eli Lilly and Novo Nordisk are expected to announce deals with the White House to offer the lowest dose of their weight-loss drugs at $149 per month, in exchange for Medicare coverage, Endpoints News reported on Tuesday, citing sources familiar with the matter. Patients in the U.S. currently pay the most for prescription medicines,…
By Arasu Kannagi Basil (Reuters) -MapLight Therapeutics debuted on the Nasdaq on Monday with a valuation of $787 million, becoming the first company to go public under a rarely used regulatory provision since the start of the U.S. government shutdown. Shares of the Redwood City, California-based company, which is developing treatments for central nervous system…
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.5% in the afternoon session after political comments introduced significant uncertainty regarding the future pricing of the company’s weight-loss and diabetes drugs, Zepbound and Mounjaro. The drop occurred after President Donald Trump suggested that the price for the GLP-1 drug category, which Eli Lilly dominates alongside…